MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Biotechnology

Healthcare
$53.42 -1.54%

-$0.64 today

Market cap
$2.65B
Beta
0.75
P/E (TTM)
-22.0
EPS (TTM)
-$1.86
52W Low $9.43High $45.85

Volume 0.73M

Average 0.65M

MBX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

MBX Biosciences, Inc. Common StockNASDAQ: MBX

Accounts Payables · Q3 FY2026 · quarter ended Sep 2026

Accounts payables turns positive

Q3 FY2026 accounts payables was $3.17M, compared with -$2.04M a year earlier. Trailing-twelve-month accounts payables was $3.05M.

Context

  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $3.17M or moves back toward the trailing-twelve-month quarterly average of $762.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$3.17M+198.1% QoQ
Last fiscal yearDec 2025
-$2.46M-162.5% YoY
LTMSep 2026
$3.05M+420.9% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+255.0%——
1 year-162.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(2.46M) USD
Year-over-year change
-162.5%

Accounts Payables vs competitors

How MBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +420.9% is the 2nd highest of 7, against a peer median of +40.4%.
MBX Competitors
Accounts Payables for MBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VKTXViking Therapeutics, Inc.LTM Jun 2026$63.52M USD+1235.7%+83.0%—
ASNDAscendis Pharma A/SLTM Sep 2026€58.15M EUR——4.8%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$24.96M USD-30.3%+142.1%8.9%
KLRAKailera Therapeutics, Inc.FY2025$4.69M USD———
BMEABiomea Fusion, Inc.LTM Mar 2026$3.1M USD-201.8%——
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$3.05M USD+420.9%——
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$1.44M USD-64.1%——
ALTAltimmune, Inc.LTM Mar 2026$453K USD+116.9%-3.3%1258.3%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$119K USD+111.0%-74.8%0.0%
Peer median (excluding MBX) —+40.4%+39.9%6.9%

Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.14M)(32.56M)(61.92M)(86.97M)
Depreciation & Amortization56K157K244K248K
Deferred Income Tax0000
Stock-Based Compensation306K2.04M5.22M8.68M
Change in Working Capital1.29M(735K)4.6M1.58M
Accounts Receivables0000
Inventory0000
Accounts Payables671K412K3.93M(2.46M)
Other Working Capital619K(1.15M)670K4.03M
Other Non-Cash Items1.36M(880K)(2.82M)(3.48M)
Operating Cash Flow(23.12M)(31.98M)(54.68M)(79.95M)
Capital Expenditures(441K)(129K)(874K)(1.93M)
Acquisitions (Net)0000
Purchases of Investments(20.22M)(63.8M)(239.47M)(358.15M)
Sales of Investments9.25M33M79.75M267.87M
Other Investing Activities0008.5M
Investing Cash Flow(11.41M)(30.93M)(160.6M)(83.71M)
Debt Repayment10M000
Common Stock Issued30K739K174.54M189.59M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(428K)(30K)(3.94M)0
Financing Cash Flow46.06M69.22M234.1M189.59M
Effect of Forex Changes0000
Net Change in Cash11.53M6.31M18.83M25.94M
Free Cash Flow(23.56M)(32.11M)(55.56M)(81.88M)

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Intrinsic Alpha fair value

Locked

Current Price

$53.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.